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doi:10.1016/j.kjms.2011.03.001Abstract Systemic lupus erythematosus (SLE) is a chronic systemic autoimmune disease. Pro-
longed complete remission is rare. Most patients with SLE need long-term treatment with
glucocorticoid and immunomodulators. However, side effects because of the above medica-
tions are common. We evaluated the effect of adding-on Dan-Chi-Liu-Wei combination
(DCLWC) on SLE patients with conventional therapy in tapering steroid and preventing disease
flare-up. This was a double-blind and randomized controlled trial. Sixty-six SLE patients were
recruited into this study and 53 patients who fulfilled the 1997 revised criteria for the classi-
fication of SLE with an SLE disease activity index (SLEDAI) score of 2e12 and a steroid
(measured with prednisolone) daily dose of less than 20 mg/d were enrolled. The patients
were randomized into either an experimental or control group. We checked the urine analysis,
hemogram, liver function, renal function, C3, C4, erythrocyte sedimentation rate, andRheumatology, Allergy and Immunology, Department of Internal Medicine, Chang Gung Memorial
hang Gung University College of Medicine, No. 123, Ta-Pei Road, Niao-Sung District, Kaohsiung City
mh.org.tw (C.-J. Chen).
vier Taiwan LLC. All rights reserved.
252 Y.-N. Liao et al.anti-dsDNA, evaluated the SLEDAI score, and recorded the steroid dose at 0 months, 3 months,
and 6 months, respectively. After 6 months of study, the C4 and blood urea nitrogen level re-
vealed a statistically significant difference in either group. There was a tendency toward
a decreased SLEDAI score in the experimental group (pZ 0.083) but not in the control group
(pZ 0.867). The steroid dose was not statistically significant in either group. Renal function
and liver function revealed no statistically significant statistics changes in either group.
Adding-on DCLWC to conventional therapy for the treatment of SLE was safe and might have
a borderline effect in decreasing disease activity, but it was not possible to taper the dosage
of steroid after 6 months of clinical trial. Therefore, a long-term follow-up and a large-scale
study are necessary to confirm the effect of DCLWC.
Copyright ª 2011, Elsevier Taiwan LLC. All rights reserved.Introduction
Systemic lupus erythematosus (SLE) is a chronic systemic
autoimmune disease predominantly involving childbearing
women. Although the 10-year survival rate for SLE patients
has improved up to 80%e90%, complete cure is rare. Most
patients with SLE need long-term treatment with gluco-
corticoids and immunomodulators to control disease
activity. However, prolonged complete remission in lupus is
rare [1]. Long-term steroid use can lead to a variety of side
effects, including central obesity, moon face, buffalo
hump, wasting of the extremities, osteoporosis, avascular
necrosis of bone, and infection. Therefore, the best way to
taper the steroid dose while concomitantly preventing
disease flare-up is an important issue to date.
At present, antimalarial drugs and immunosuppressive
agents, such as azathioprine or cyclophosphamide, have
been used to resolve the above-mentioned problems.
However, side effects because of these medications are
common. Antimalarial drugs can cause macular damage [2]
and myopathy [3]. Azathioprine can cause myelosup-
pression [4], hepatotoxicity [5], and lymphoproliferative
disorders [6]. Cyclophosphamide can cause immunosup-
pression [7], infertility [8], and bladder cancer [9]. Because
of their concern about these side effects, most SLE patients
look desire to an alternative therapy [10,11].
Traditional Chinese medicine (TCM) is one of the most
well-organized complementary and alternative medicine
systems, with more than 2,000 years of clinical experience.
Therefore, we wanted to find an alternative treatment
using TCM to help SLE patients achieve long-term health,
with a lower steroid dose and less disease flare-up. Our
research team included immunologists, TCM experts, and
a pharmacy specialist who designed the Dan-Chi-Liu-Wei
combination (DCLWC), which is composed of two classical
formulas: Liu-Wei-Di-Huang Wan (LWDHW) and Dan-Chi San
(also known as Fufang Danshen tablets). LWDHW, one of the
most famous TCM formulas, was originated by Qian-Yi,
a TCM physician in the Northern Sung Dynasty (960e1127
A.C.). Recent studies have revealed that LWDHW has
immunosuppressive effects [12].
Dan-Chi San, also known as Fufang Danshen tablets,
originated at the Shanghai Secondary Pharmaceutical
Factory of Traditional Chinese Medicine. It was developed
in 1975 and has been produced since 1977. It is a common
TCM and has been used for the treatment of coronary artery
disease in China for more than 30 years [13], and it has
been documented in the Pharmacopoeia of the People’sRepublic of China from the third edition (1977) [14]. There
are other preparations, such as Compound Danshen Drip-
ping Pill [15] and a compound injection of Danshen. It has
been reported that Dan-Chi San has biological activities
that improve microcirculation, dilate coronary artery, and
improve myocardial ischemia. In clinical practice, it has
been used clinically for coronary artery disease, cardiac
angina, diabetes microvascular complications, and athero-
sclerosis [16e18]. Women with SLE have strikingly higher
rates of premature cardiovascular disease, with up to a 50-
fold increase in the incidence of cardiovascular complica-
tions over age- and sex-matched control subjects [19].
Taken together, the DCLWC is accepted to be beneficial
in tapering the steroid dose and decreasing the frequency
of disease flare-up in SLE patients. Therefore, we evaluated
the effect of DCLWC on SLE patients, using a double-blind
and randomized controlled trial.
Material and methods
Recruitment of patients
This trial was performed at Chang Gung Memorial Hospital-
Kaohsiung Medical Center and Chung-Ho Memorial Hospital,
Kaohsiung Medical University from February 2007 to
December 2007 (Clinical trial registration number:
ISRCTN73842582). The study protocol was evaluated and
approved by the Institutional Review Boards of Chang Gung
Memorial Hospital-Kaohsiung Medical Center and Chung-Ho
Memorial Hospital. We recruited SLE patients from the
outpatient clinic. All participants gave their written
informed consent, which was approved by the Institutional
Review Board. Inclusion criteria were all of the following:
patients meeting the 1997 revised criteria for the classifi-
cation of SLE [20], SLE disease activity index (SLEDAI) score
[21] of 2e12, and a steroid (measured with prednisolone)
daily dose less than 20 mg/d, the minimum dose being
2.5 mg/d.
Exclusion criteria were as follows: pregnancy, age under
18 or more than 60 years, and renal function impairment
(serum creatinine level higher than 1.4 mg/dL).
Study design
This was a double-blind, randomized controlled trial. SLE
patients with mild-to-moderate disease activity (SLEDAI
2e12) were recruited and randomly assigned to either
Traditional Chinese medicine formula in SLE 253a control or an experimental group. Simple randomization
was achieved using a sequence of random numbers from
a computer-generated sequence. “T” was allocated to
“experiment” and “C” to “control”. In the “T” group,
patients were treated with conventional medicines and
100% TCM. In the “C” group, patients were treated with
conventional medicines and 10% TCM. All TCM packages,
including both experimental and control groups, were
marked with sequence number only. Neither patients nor
doctors or research assistants knew the content of TCM
packages. The sequence of random numbers was sealed in
a box with signature by the principle investigator until the
study was completed. All SLE patients were allowed to
continue their original therapy using Western medicine,
including glucocorticoid, antimalaria drugs, and/or other
immunomodulators.
DCLWC is composed of two well-known formulas:
LWDHW (Table 1) and Dan-Chi San (Table 1). The study
medication was administered as pills within a package to
both experimental and control groups. The experimental
group received a package of TCM each time via oral intake
in total three times per day as an add-on therapy. Each
package contained 2.7 g of LWDHW and 125 mg of Dan-Chi
San (100%) together. The dosage was given according to
the manufacturer’s instructions. In the control group, 10%
of LWDHW with 90% starch and 10% Dan-Chi San with 90%
starch were used.
The primary outcome was the change of steroid dosage
after 6 months of combined therapy (DCLWC and regular
medications). The secondary outcome was the frequency
of disease flare-up and the change in the immunologic
index (C3, C4, anti-dsDNA) after 6 months of combined
therapy.
Evaluation of adverse effects
Adverse effects, including abdominal pain, dyspepsia,
constipation, diarrhea, edema, headache, abnormal renal
function test, abnormal liver function test, and abnormal
hematologic test were recorded. All patients were questedTable 1 Composition of Dan-Chi-Liu-Wei combination
Liu-Wei-Di-Huang Wan
Scientific name of Chinese herbs Amount of every 25 g
extractum (g)
Radix Rehmanniae Preparata* 8
Rhizoma Dioscoreae* 4
Poriae* 3
Cortex Moutan Radicis* 3
Rhizoma Alismatis* 3
Fructus Corni* 4
Extractumy
Starch
Every 8 g of extract fine granules contained 4 g starch and 4 g extractu
“*”) and the extractum (marked “y”) is 25:4Z 6.25:1. Starch was use
a Polyethylene glycols were used as an excipient in Dan-Chi San.systemically at the 3rd and 6th months of this study,
respectively.
Laboratory test and evaluation of disease activity
Complete blood routine, erythrocyte sedimentation rate,
urine analysis, blood urea nitrogen (BUN), creatinine,
alanine transaminase, aspartate transaminase (AST), C3,
C4, anti-dsDNA were measured at baseline, 3 months, and 6
months, respectively. The disease activity of SLE was
evaluated at baseline, 3 months, and 6 months, using the
SLEDAI developed by Bombardier et al. [21]. If SLEDAI score
increased more than 3 compared with previous SLEDAI
score, it was regarded as disease flare-up [22].
Statistics
Statistical analyses were performed with Statistics Package
for Social Science software 11.5 for windows (SPSS Inc.,
Chicago, IL, USA). Descriptive data were presented as
mean standard deviation as required according to the
normal distribution of the parameters. Figures were
pictured with repeated measurements. Statistical compar-
ison between DCLWC experimental or control group was
performed using the analysis of variance, whereas the
paired t test was used for comparison between pre- and
posttreatment. Statistically significant probability was
expressed as p value less than 0.05.
Results
Patient enrollment and assignment
Weopened this trial, including inclusion criteria by poster, to
502 patients with SLE; followed up at outpatient department
of Chang Gung Memorial Hospital-Kaohsiung Medical Center
and Chung-Ho Memorial Hospital, Kaohsiung Medical
University. Sixty-six volunteers volunteered for the trial.
After screening, 53 patients who fulfilled the enrollmentDan-Chi San
Scientific name of Chinese herbs Amount per pill (25 mg
each pill) (mg)
Radix Salviae Miltiorrhizae 17.5
Radix Notoginseng 3.4
Borneolum Syntheticum 0.2
Polyethylene glycolsa 3.9
m from Chinese herbs. The ratio of the six Chinese herbs (marked
d as an excipient in Liu-Wei-Di-Huang Wan combination.
SLE patients (n = 502) 
Patients screened (n = 66) 
 Enrolled and randomized (n = 53) 
Control group assigned and 
received (n = 24) 
Experimental group assigned 
and received (n = 29) 
23 patients 25 patients 
23 patients 23 patients 
Excluded (n = 13) 
Not meeting inclusion criteria 
 SLEDAI score <2 (n = 10) 
 Abnormal liver function test 
(n = 1) 
 Severe upper respiratory 
infection (n = 1) 
 Family factor (n = 1)
Withdrawal (n = 1) Withdrawal (n = 3) 
Other (n = 1)a 
Completed 3
months of study 
Completed 6
months of study 
Could not be followed 
because of being busy (n = 1) 
Family factor (n = 1) 
Figure 1. Flow chart of the patients who participated in the
clinical trial. a One patient was lost to follow-up at the 3rd
month but came back again at the 6th month. SLEZ systemic
lupus erythematosus; SLEDAIZ SLE disease activity index.
254 Y.-N. Liao et al.criteria were randomly assigned to either the control or the
experimental group (Fig. 1). Forty-eight patients completed
3 months of the trial, and 46 completed 6 months. The
baseline characteristics of both groups that completed 6
months study showed no significant differences (Table 2). No
patients changed any disease-modifying antirheumatic
drugs, such as hydroxychloroquine and azathioprine; only
steroid dose was adjusted according to disease activity
during the study period.
Steroid dosage change
There was no significant change of steroid dose after 6
months in the experimental (pZ 0.715) (Table 3) or control
group compared with baseline (pZ 0.947) (Table 3).Table 2 Demographic and baseline characteristics of patients
Characteristics Control
(nZ 23) (mean
Age (yr) 36.26 9.70
Systolic blood pressure (mmHg) 108.52 11.52
Diastolic blood pressure (mmHg) 68.60 9.25
Heart rate (bpm/min) 77.56 7.93
Body height (cm) 158.52 5.08
Body weight (kg) 51.78 9.22
BMI (kg/m2) 20.55 3.16
Basic data of the experimental and control group patients who comp
BMIZ body mass index; bpmZ beats per minute; SDZ standard devFrequency of disease flare-up
During the 6-month period of DCLWC add-on therapy, the
frequency of disease flare-up in the experimental group
was 8.6% (2/23, 2 patients with 2 flare-ups). This was lower
than the 13% (3/23, 3 patients with 4 flare-ups) in the
control group. There was no significant difference between
the two groups. However, there was one very severe
disease flare-up resulting in admission in the control group,
in a patient who suffered two flare-ups in the course of
study, but there were no severe disease flare-ups in the
experimental group.
SLEDAI score
In the experimental group, there was a tendency toward
a decreased SLEDAI scores after 6 months of DCLWC
add-on therapy compared with baseline (pZ 0.083)
(Table 3). In contrast, there was no significant change in
the control group compared with the base line
(pZ 0.867) (Table 3).
Serologic change
Anti-dsDNA
There was no significant change of serum level of anti-
dsDNA after 6 months in the experimental (pZ 0.157)
(Table 3) or control group compared with base line
(pZ 0.942) (Table 3).
C3 and C4 level
There was no significant change in the serum level of C3
after 6 months of DCLWC add-on therapy in the experi-
mental group (pZ 0.978) (Table 3) or in the control group
(pZ 0.123) (Table 3). There was a significant elevation of
the serum level of C4 after 6 months of DCLWC add-on
therapy in the experimental group (p< 0.01) (Table 3)
and in the control group (p< 0.01) (Table 3).
Erythrocyte sedimentation rate
There was a no significant change in the serum level
of erythrocyte sedimentation rate after 6 months of
DCLWC add-on therapy in the experimental group
(pZ 0.241) (Table 3) or in the control group (pZ 0.116)
(Table 3).SD)
Experimental
(nZ 23) (mean SD)
p
36.21 8.90 0.987
111.21 14.16 0.483
72.08 9.65 0.219
79.39 9.21 0.475
160.43 5.79 0.241
56.39 7.86 0.075
21.96 3.28 0.146
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In the experimental group, there was a mild increase of the
serum level of AST after 6 months of DCLWC add-on therapy
(pZ 0.102) (Table 3), but the serum level of AST was still in
the normal range. However, there was no significant change
in the serum level of AST in the control group (pZ 0.162)
(Table 3). In addition, there was no significant change in the
serum level of alanine transaminase in the experimental
group (pZ 0.713) (Table 3) or in the control group
(pZ 0.550) (Table 3).
Renal function test
After 6 months of add-on therapy, there was a significant
decrease of the serum level of BUN in the experimental
group (pZ 0.048) (Table 3) and in the control group
(pZ 0.048) (Table 3). There was no significant change in
the serum level of creatinine in the experimental group
(pZ 0.622) (Table 3) or in the control group (pZ 0.515)
(Table 3).
Adverse effects
During the study, very few patients experienced slightly
adverse effects. These adverse effects included gingivitis,
fever, skin rash, diarrhea, and so on (Table 4). There was no
difference in the frequency of adverse effects between the
experimental and control groups.
Real compliance of patients
During the study, the accountability of returned drug in the
experimental group was 15.02% and in the control group
was 11.08%. There was no difference in the accountability
of returned drug between the experimental and control
groups.
Discussion
This was the first double-blind randomized controlled trial
using TCM add-on therapy to taper steroid dose, while
concomitantly preventing disease flare-up. Only C4 and
BUN improved significantly, but these improvements were
also found in the control group. This phenomenon might be
because of the therapeutic effect from conventional
treatment with steroid and immunomodulators. The steroid
dose showed no significant decrease after 6 months of TCM
add-on therapy, but the SLEDAI score showed a decreasing
tendency in the experimental group after 6 months of
treatment. This suggested that TCM add-on therapy might
have a borderline effect to patients with SLE. However,
another possibility was that the finding might be biased
because of the SLEDAI score appeasing to be higher in the
experimental group at the beginning of the study. Between
these two possibilities, the former was favored by our team
based on clinical observation. The number of the patients
who completed 6 months study was too small (total 46
patients) and the duration of study was only 6 months. This
might be the major reason to explain why there was no
significant effect between groups.
The frequency of disease flare-up in the experimental
group after 6 months of therapy was 8.6% (2/23), which was
Table 4 Classification and number of adverse effects in the control and experimental groups
Adverse effects Control (nZ 23) Experimental (nZ 23) Total
Gingivitis, headache, and cold extremities 1 0 1
Fever 0 1 1
Skin rash 2 0 2
Constipation 1 0 1
Diarrhea and urinary tract infection 1 0 1
Upper respiratory infection 1 1 2
Dysmenorrhea 2 0 2
Gastrointestinal tract dysfunction 0 2 2
Number of adverse effects (%) 8 (34.8) 4 (17.4) 12
256 Y.-N. Liao et al.less than the 13% (3/23) in the control group. There was one
very severe flare-up resulting in the admission of a patient
in the control group who suffered two flare-ups during the
study period, but there was none in the experimental
group. Although the incidence of flare-ups did not reach
statistical significance between the two groups, a longer
follow-up (1 year or more) in a future study may provide
a more solid answer as to know whether DCLWC can
decrease the frequency of disease flare-up or not.
The safety of TCM therapy is a major concern to date.
Some herbs, such as Aristolochia fangchi (known as “Guang
Fang Ji” in Chinese medicine) and Aristolochia manschur-
iensis (known as “Guan Mutong” in Chinese medicine) have
been reported to cause renal toxicity [23]; however, no
herbs used in DCLWC have been reported to cause renal
toxicity. After 6 months of observation, DCLWC was shown
to be really safe and without renal toxicity. Although AST
was slightly elevated in the experimental group, it was still
within the normal range. However, a further work-up is
mandatory to ensure the safety of DCLWC in relation to the
liver.
One clinical trial has been conducted using TCM in SLE
patients. It was reported that the Liuwei Dihuang pill can
improve the therapeutic effectiveness and counteract the
adverse effects of steroid and immunosuppressive agents in
the treatment of SLE, and reduce the recurrence of the
disease [24]. There were several drawbacks of the study:
first, it lacked of double-blind design; second, there was
a lack of disease activity scores before and after treatment;
and third, the steroid dose was tapered by schedule,
despite the disease activity of SLE.
In conclusion, add-on therapy of DCLWC to the conven-
tional therapy for the treatment of SLE was safe and might
have a borderline effect on decreasing disease activity, but
it was unable to assist in tapering the dosage of steroid
after 6 months of clinical trial. However, long-term follow-
up and large-scale studies are necessary in the future.Acknowledgments
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